Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion

Retina

Volumn 29, Issue 7, 2009, Pages 913-925

  Gregori, Ninel Z ^a,b   Rattan, Ginger Henson ^a   Rosenfeld, Philip J ^a   Puliafito, Carmen A ^c   Feuer, William ^a   Flynn Jr , Harry W ^a   Berrocal, Audina M ^a   Al Attar, Luma ^a   Dubovy, Sander ^a   Smiddy, William E ^a   Schwartz, Stephen G ^a   Lee, Wen Hsiang ^a   Murray, Timothy G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Avastin; Bevacizumab; Branch retinal vein occlusion; BRVO; Hemiretinal vein occlusion; HRVO; Intravitreal injection; Macular edema; Vascular endothelial growth factor; VEGF

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB; RANIBIZUMAB; STEROID;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HEMIRETINAL VEIN OCCLUSION; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA TEAR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRABECULECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR EDEMA; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 68249096210     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181aa8dfe     Document Type: Article

References (51)

1. Scott IU. Vitreoretinal surgery for complications of branch retinal vein occlusion. Curr Opin Ophthalmol 2002;13:161-166. (Pubitemid 34518200)
2. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-282.
3. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999;19:1-5.
4. Garcia-Arumi J, Martinez-Castillo V, Boixadera A, Blasco H, Corcostegui B. Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator. Retina 2004;24:530-540. (Pubitemid 39079877)
5. Hansen LL, Wiek J, Arntz R. [Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion]. Fortschr Ophthalmol 1988;85:514-516.
6. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 1998;116:43-52. (Pubitemid 28098893)
7. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-883.
8. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339. (Pubitemid 41073113)
9. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623.e1.
10. Byeon SH, Kwon YA, Oh HS, Kim M, Kwon OW. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther 2007;23:387-394. (Pubitemid 350195064)
11. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
12. Arevalo JF, Garcia-Amaris RA, Roca JA, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 2007;33:2098-2105.
13. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309-315.
14. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997;64:505-517. (Pubitemid 27321334)
15. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
16. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828.
17. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71. (Pubitemid 26026196)
18. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
19. Abegg M, Tappeiner C, Wolf-Schnurrbusch U, Barthelmes D, Wolf S, Fleischhauer J. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008;8:18.
20. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008;19:234-238.
21. Chalam KV, Keshavamurthy R, Brar VS. Spectral domain OCT documented resolution of recalcitrant macular edema after intravitreal bevacizumab in branch retinal vein occlusion. Eur J Ophthalmol 2008;18:831-833.
22. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241-1247.
23. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;2007;27:141-149.
24. Gündüz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye 2008;22:1168-1171.
25. Hoh AE, Schaal KB, Dithmar S. [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland] Ophthalmologe 2007;104:290-294.
26. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27-33.
27. Jaissle GB, Ziemssen F, Petermeier K, et al. Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2006;103:471-475. (Pubitemid 43892185)
28. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-355.
29. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522.
30. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606. (Pubitemid 46452523)
31. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin(R)) for macular edema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
32. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-425. (Pubitemid 46624280)
33. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 2009;223:124-127.
34. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 2009;29:511-515.
35. Schaal KB, Höh AE, Scheuerle A, Schütt F, Dithmar S. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2007;104:285-289.
36. Spandau U, Wickenhäuser A, Rensch F, Jonas J. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 2007;85:118-119. (Pubitemid 46140171)
37. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436. (Pubitemid 47423323)
38. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219. (Pubitemid 351643150)
39. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008;37:591-593.
40. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431.
41. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895. (Pubitemid 44547441)
42. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511. (Pubitemid 44620390)
43. Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 2008;115:319-323.
44. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.
45. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-855. (Pubitemid 41456575)
46. Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.
47. Brown GC, Kimmel AS, Magargal LE, Morrison DL, Sanborn GE. Progressive capillary nonperfusion in temporal branch retinal vein obstruction. Ann Ophthalmol 1989;21:290-293.
48. Hofman P, van Blijswijk BC, Gaillard PJ, Vrensen GF, Schlingemann RO. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol 2001;119:861-866. (Pubitemid 32530315)
49. Danis RP, Wallow IH. Microvascular changes in experimental branch retinal vein occlusion. Ophthalmology 1987;94:1213-1221. (Pubitemid 17149327)
50. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385. (Pubitemid 34171588)
51. Schachat AP, Chambers WA, Liesegang TJ, Albert DA. Safe and effective. Ophthalmology 2003;110:2073-2074.